Holen Sie sich die Stockscreener-App
1.17
3.31%
-0.04
Schlusskurs vom Vortag:
$1.21
Offen:
$1.21
24-Stunden-Volumen:
90,034
Relative Volume:
0.02
Marktkapitalisierung:
$5.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.66M
KGV:
-0.1435
EPS:
-8.156
Netto-Cashflow:
$-11.09M
1W Leistung:
-10.69%
1M Leistung:
-11.36%
6M Leistung:
-62.97%
1J Leistung:
-81.43%
1-Tages-Spanne:
$1.15
$1.21
1-Wochen-Bereich:
$1.15
$1.34
52-Wochen-Spanne:
$1.15
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Vergleichen Sie PHIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.17 | 5.59M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
Groundbreaking Cancer Treatment Data: Phio's Dual Immunotherapy Candidates Show Promise - Stock Titan
Phio stock hits 52-week low at $1.22 amid sharp annual decline - Investing.com
Phio stock hits 52-week low at $1.22 amid sharp annual decline By Investing.com - Investing.com South Africa
Phio Pharmaceuticals Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Virtu Financial LLC Makes New Investment in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update - TradingView
Phio's Cancer Drug Shows Complete Response as Company Slashes Losses by 33% - Stock Titan
Phio Pharmaceuticals (PHIO) Expected to Announce Earnings on Monday - Defense World
PHIO PHARMACEUTICALS CORP- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
PHIOPhio Pharmaceuticals Corp Latest Stock News & Market Updates - Stock Titan
American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting - Quantisnow
Phio Reports 50% Complete Response Rate in Skin Cancer Trial - StockTitan
Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study - Newsfile
PHIO stock touches 52-week low at $1.25 amid sharp annual decline - Investing.com Australia
Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated - MSN
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Can Phio's Novel siRNA Cancer Technology Impress Investors at Upcoming Roadshow? - StockTitan
PHIO stock touches 52-week low at $1.48 amid market challenges - Investing.com
PHIO stock touches 52-week low at $1.48 amid market challenges By Investing.com - Investing.com South Africa
Brokers Offer Predictions for PHIO FY2024 Earnings - Defense World
Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals Appoints David Deming to Board - TipRanks
Phio Pharmaceuticals expands board with new director By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals Corp. Appoints David H. Deming to Board of Directors -February 20, 2025 at 09:54 am EST - Marketscreener.com
H.C. Wainwright maintains Buy rating, $4 target on Phio Pharma stock - Investing.com
Phio Pharmaceuticals expands board with new director - Investing.com
Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors - Newsfile
Phio Pharmaceuticals (NASDAQ:PHIO) Given “Buy” Rating at HC Wainwright - Defense World
PHIO Stock: The Biotech Breakthrough You Can't Ignore! Is This the Future of Immunotherapy? - Elblog.pl
Reviewing BridgeBio Pharma (NASDAQ:BBIO) & Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals (NASDAQ:PHIO) Shares Down 5.8% – Should You Sell? - Defense World
Phio Pharma (NASDAQ:PHIO) Stock Quotes, Forecast and News Summary - Benzinga
Inside Phio's Revolutionary siRNA Cancer Treatment: CEO Reveals Clinical Progress - StockTitan
Revolutionary Cancer Treatment or Environmental Savior? - Elblog.pl
Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis - MarketBeat
Phio Pharmaceuticals CEO to Present Breakthrough Cancer Treatment at Renmark Virtual Roadshow - StockTitan
Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Newsfile
Phio Pharmaceuticals Secures $1.83M Direct Offering to Advance Cancer Treatment Pipeline - Stock Titan
We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run - MSN
Phio Pharmaceuticals Raises $1.83M in Direct Offering with Warrant Coverage at $3.00/Share - StockTitan
Stock market news: Phio Pharmaceuticals +50.19%, DatChat +46.01% among top gainers during mid day trading - Business Upturn
Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Financial Content
Biotech Alert: Searches spiking for these stocks today - TipRanks
Stock market today: Phio Pharmaceuticals -20.76%, Soligenix -20.15% among biggest losers in early trading - Business Upturn
Phio Pharmaceuticals Raises $2.5M Through Direct Offering at $3.00 Per Share - StockTitan
Phio Pharmaceuticals sharply lower on equity offering - MSN
Stock market news: PTL -68.18%, Springview Holdings -41.63% among biggest losers during mid day trading - Business Upturn
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):